Physician profile
Shefali Shah
NPI 1578525432
$4,367.80
in general payments reported to CMS, 2019-2025
44 companies · $856 in 2025
The $856 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $532 · 2021: $556 · 2022: $485 · 2023: $770 · 2024: $725 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $613.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $587.43 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $474.51 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $414.59 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $327.50 | 2019-2020 | |
| Novo Nordisk INC | $270.24 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $204.40 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $109.50 | 2024-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.05 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $78.95 | 2023 | |
| Janssen Biotech, INC. | $74.64 | 2023-2025 | Stelara, Tremfya |
| Bausch Health US, LLC | $73.41 | 2020-2025 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $72.19 | 2022 | |
| Ferring Pharmaceuticals INC. | $68.05 | 2022-2023 | Rebyota, Cimzia |
| Avanir Pharmaceuticals, INC. | $68.04 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shefali Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.